Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691699 | 0.82 | LMNA (0.60) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL2678538 | 0.82 | LMNA (0.60) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL19102158 | 0.81 | POLB (0.59) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL15023835 | 0.81 | LMNA (0.84) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL31463657 | 0.81 | LMNA (0.84) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL12545817 | 0.80 | CYP2D6 (0.55) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL12915262 | 0.79 | KDM4E (0.57) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL1520483 | 0.79 | SMN1; SMN2 (0.58) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL11697197 | 0.79 | TDP1 (0.67) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL16790661 | 0.79 | TDP1 (0.67) | KDM4ELMNAKMT2ACYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-10869872-B2 | — | — | 2020-12-22 | — | — | US | disclosed |
| EP-3277687-B1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER | Celon Pharma Sa (PL) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019100743-A1 | PARP-1 AND PI3K DUAL TARGET INHIBITOR COMPRISING BENZOFURAN | 中国药科大学 | 2019-05-31 | — | — | WO | disclosed |
| US-20190151327-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2019-05-23 | — | — | US | disclosed |
| EP-2984088-B1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10226468-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3052504-B1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIV BASEL (CH) | 2019-02-06 | — | — | EP | disclosed |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9757382-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151327-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 386/4885LMNA 4307/4885KMT2A 698/4885 |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 386/4885LMNA 4307/4885KMT2A 698/4885 |
| US-10869872-B2 | — | NRAS, KRAS, BRAF | KDM4E 293/4885LMNA 4406/4885KMT2A 643/4885 |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 386/4885LMNA 4307/4885KMT2A 698/4885 |
| US-10226468-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | NRAS, KRAS, BRAF | KDM4E 386/4885LMNA 4307/4885KMT2A 698/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885LMNA 3182/4885KMT2A 2804/4885 |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | MTOR, RICTOR, PIK3R4 | KDM4E 572/4885LMNA 2271/4885KMT2A 2474/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885LMNA 3182/4885KMT2A 2804/4885 |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | NRAS, KRAS, BRAF | KDM4E 386/4885LMNA 4307/4885KMT2A 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.